Xin Han, MD, MS
Department of Laboratory Medicine, Division of Pathology-Lab Medicine Div
Present Title & Affiliation
Primary Appointment
Medical Director, Section of Hematology/Coagulation, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Section of Reference Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Section of Point-of-Care Testing, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1990 | Shanghai Second Medical University, Shanghai, CN, Pathophysiology of Hematology, M.S |
| 1987 | Wenzhou Medical College, Wenzhou, CN, MD |
Postgraduate Training
| 2007-2008 | Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2007 | Heart of Leadership Core Skills, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2005 | Veridex CTC Test, Circulating Tumor Cell Identification, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2005 | Minifellowship (Observership), Coagulation Service, Massachusetts General Hospital, Boston, Massachusetts |
| 2004-2005 | Clinical Fellowship, Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2000-2004 | Clinical Residency, Pathology, Temple University Hospital, Philadelphia, Pennsylvania |
| 1994-2000 | Research Fellow, Hematology, Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, Missouri |
| 1990-1993 | Resident, Hematology, First Affiliated Hospital to Wenzhou Medical College, Wenzhou |
| 1988-1990 | Visiting Scholar, Laboratory of Molecular Biology, State Key Laboratory of Molecular Biology Shanghai Institute of Biochemistry, Shanghai |
| 1986-1987 | Intern, First Affiliated Hospital to Wenzhou Medical College, Wenzhou |
Licenses & Certifications
| 2005 | Texas Medical Board |
| 2005 | American Board of Pathology, Hematology |
| 2004 | American Board of Pathology, Anatomic and Clinical Pathology |
| 1998 | ECFMG |
| 1998 | USMLE Tests: Step I: Passed |
Experience & Service
Faculty Academic Appointments
Associate Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2018
Assistant Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Attending Physician, Internal Medicine, First Affiliated Hospital to Wenzhou Medical College, Wenzhou, 1993 - 1994
Administrative Appointments/Responsibilities
Medical Director, Section of Hematology/Coagulation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Medical Director, Section of Reference Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - Present
Medical Director, Section of Point-of-Care Testing, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Other Professional Positions
Member, Board of Directors, Chinese American Pathologist Association (CAPA), Houston, TX, 2020 - Present
Co-Chair, CAPA Membership Committee, Chinese American Pathologist Association (CAPA), Houston, TX, 2018 - Present
Member, CAPA Membership Committee, Chinese American Pathologist Association (CAPA), Washington, D.C, MD, 2017 - Present
Member, Diploma Program Coordinating Committee for Clinical Chemistry Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Observer, CLSI Subcommittee on POC Blood Glucose Testing (POCT12) in Acute and Chronic Care Facilities, Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, 2008 - 2009
Member of CAP Member Research Panel, College of American Pathologists, Northfield, IL, 2005 - 2010
Extramural Institutional Committee Activities
Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2014 - 2017
Serving the steward of the institutional policy on the Waived POC testing, CLN 0618, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Chair, Point-of-Care Test Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Anticoagulant Expert-Annual Review, Clinical Effectiveness Subcommittee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Member, National Patient Safety Goal 3E Focus Group, The University of Texas MD Anderson Cancer Center, 2008 - 2009
Alternate Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present
Member, Tissue Committee of Temple University Hospital, The University of Texas MD Anderson Cancer Center, 2003 - 2004
Honors & Awards
| 2022 - 2023 | Nominee for Division Faculty Educator Award - 2023, MD Anderson Cancer Center |
| 2020 - 2021 | CAPA President Award-2021, Chinese American Pathology Association |
| 2018 - 2020 | Member of The Year Award, Chinese American Pathologist Association |
| 2006 - 2008 | Visiting Professorship, Wenzhou Medical College |
| 2004 - 2005 | Fellowship Award, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center |
| 1991 | Second Grade Award of Chinese Science & Technology Association, Chinese Science and Technology Association Wenzhou Branch |
| 1982 - 1987 | Best student of the year, Wenzhou Medical College |
| 1982 - 1986 | First Award (top 1 %) and Second Award (top 10 %) for academic excellence, two times, respectively during medical education courses, Wenzhou Medical College |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2024. Enhancing White Blood Cell Classification through AI Analysis of CellaVision Images in Monocytosis Cases. Conference. United States and Canadian Academy of Pathology’s 113th Annual Meeting. Baltimore, MD, US.
- 2023. The involvement of bilateral parotid lymphoepithelial cysts as the initial presentation of t-cell prolymphocytic leukemia with t(X;14) (q28;q11). Conference. SH-EAHP 2023 Workshop. Houston, TX, US.
- 2016. Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model. Conference. Post Presentation. San Diego, CA, US.
- 2014. Expression of MicroRNA-150 Is Significantly Decreased in T-Acute Lymphoblastic Leukemia (T-ALL) and Inhibits T-ALL Cell Growth. Conference. Post presentation. San Diego, CA, US.
- 2010. Inactivation of INK4a/ARF accelerates the development of PTEN deficient T-ALL. Conference. Post presentation. Orlando, FL, US.
- 2010. Hypermethylation of DBCCR1 gene in acute myeloid leukemia. Conference. Post Presentation. Washington DC, DC, US.
- 2010. Aberrant PTEN expression pattern in acute myeloid leukemia. Conference. Post Presentation. Washington DC, DC, US.
- 2009. Inhibition of HDM4 induces p21 expression in mantle cell lymphoma. Conference. Post presentation. Boston, MA, US.
- 2008. Analysis of HDM4 expression, a key regulator of p53, in B-cell Non-Hodgkin lymphomas: the HDM4 splice mRNA variant is aberrantly overexpressed in mantle cell lymphoma. Conference. Poster presentation at USCAP Annual Meeting. Denver, CO, US.
- 2007. Dasatinib induced platelet dysfunction. Conference. Poster presentation at American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2007. Circulating Tumor Cells (CTCs) and prognostic stratification in metastatic breast cancer: need for a modification of the staging system?. Conference. Poster presentation at San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2007. Thrombin-releasable protein Z-dependent protease inhibitor identified in platelets and is likely due to uptake from plasma. Conference. Poster presentation at American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2007. A novel type of inclusion in peripheral blood neutrophils. Conference. Post presentation. New Orleans, LA, US.
- 2007. Down-regulation of HDM4 is associated with up-regulation of P21 and growth arrest in leukemia cells. Conference. Poster presentation at USCAP Annual Meeting. San Diego, CA, US.
- 2005. MDMX is widely expressed in adult precursor B cell acute lymphoblastic leukemia and is a potential therapeutic target. Conference. Post presentation. Atlanta, GA, US.
- 2005. MDMX is widely expressed in adult pre-B acute leukemia (ALL) and is a potential therapeutic target. Conference. Post presentation. San Antonio, TX, US.
- 1999. Characterization of a protein Z-dependent plasma protease inhibitor. Conference. Oral presentation. New Orleans, LA, US.
International Presentations
- 2008. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces the expression of p21. Conference. Post Presentation. Bordeaux, FR.
- 1990. Determination of plasma and tissue t-PA, PAI, Fn in patients with digestive tumor and its relationship with metastasis. Conference. Oral Presentation. Suzhou, CN.
- 1990. Significance of the contrast of tumor plasminogen activator with fibronectin content in the pathogenesis of cancer metastasis. Conference. Oral presentation. Hangzhou, CN.
- 1990. Study on monoclonal antibodies specific for activation peptides in human Factor IX and Factor X. Conference. Oral presentation. Hangzhou, CN.
- 1989. Significance of the reversible binding of tissue plasminogen activator with fibronectin. Conference. Post Presentation. Tokyo, JP.
Formal Peers
- 2020. Breast-Implant Anaplastic Large Cell Lymphoma. Visiting, US.
- 2019. Systemic Diseases Manifested in Peripheral Blood. Visiting. Los Angles, CA, US.
- 2006. Protein Z and Protein Z-dependent Protease Inhibitor-a Novel Anticoagulant Pathway. Invited. Shanghai, CN.
- 2006. Protein Z and Protein Z-dependent Protease Inhibitor-a Novel Anticoagulant Pathway. Invited. Shanghai, CN.
- 2006. Protein Z and Protein Z-Dependent Protease Inhibitor-a Novel Anticoagulant Pathway. Visiting. Shanghai, CN.
- 2006. WHO Classification of Mature B-Cell Lymphoma. Invited. Zhejiang, CN.
- 2006. WHO Classification of Mature B-Cell Lymphoma. Visiting. Wenzhou, CN.
- 2003. Regulation of the Fibrinolysis System. Invited. Philadelphia, PA, US.
- 2000. Protein Z-dependent Protease Inhibitor. Invited. Philadelphia, PA, US.
Grant & Contract Support
| Date: | 2005 - 2010 |
| Title: | Start-up fund for Assistant Professor Clinical Tenure Track |
| Funding Source: | MD Anderson Cancer Center Division of Pathology and Laboratory Medicine |
| Role: | PI |
| Date: | 2004 - 2005 |
| Title: | Fellowship Award 2004-2005 |
| Funding Source: | MD Anderson Cancer Center Division of Pathology and Laboratory Medicine, |
| Role: | PI |
| Title: | To analyze HDM4 expression, a negative regulator of p53, in B-cell non-Hodgkin’s lymphoma |
| Funding Source: | Division of Pathology and Laboratory Medicine |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Jia, Y, Zhang, W, Basyal, M, Chang, KH, Ostermann, LB, Burks, JK, Ly, C, Mu-Mosley, H, Zhang, Q, Han, X, Fogler, WE, Magnani, JL, Lesegretain, A, Zal, A, Zal, T, Andreeff, M. FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia 37(6):1379-1383, 2023. e-Pub 2023. PMID: 37085610.
- Zhang XH, Zhou JH, Han X, Wang ED, and Zhang LS. Update on the Classification and Diagnostic Approaches of Mature T-Cell Lymphomas. Archives of Pathology & Laboratory Medicine 146(8):947-952, 2022. e-Pub 2022. PMID: 34524423.
- Xu-Monette, Z, Wei, L, Fang, X, Au, Q, Nunns, H, Nagy, M, Tzankov, A, Zhu, F, Visco, C, Bhagat, G, Dybkær, K, Chiu, A, Tam, W, Zu, Y, Hsi, ED, Hagemeister, FB, Sun, X, Han, X, Go, H, Ponzoni, M, Ferreri, AJ, Møller, MB, Parsons, BM, Van Krieken, JH, Piris, MA, Winter, JN, Li, Y, Xu, B, Albitar, M, You, H, Young, KH. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research 28(5):972-983, 2022. e-Pub 2022. PMID: 34980601.
- Young K, Xu-Monette ZJ, Wei L, Fang XS, Au QY, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu YL, Hsi E, Hagemeister F, Sun XP, Han X, Go HJ, Ponzoni M, Ferreri AJM, Moller M, Parsons B, van Krieken JH, Piris MA, Winter J, Li Y, Xu B, You H, and Albitar M. Genetic subtyping and phenotypic characterization of the immune microenvironment. Clinical Cancer Research 28(5):972-983, 2022. e-Pub 2022.
- Xia MR, Wu L, Sun XP, Han X, Yan HG, Huang J, Zhang YH, Hu ZH, Zu YL, Yin CC, Qiu XY. Next-generation sequencing revealed a distinct immunoglobulin repertoire with specific mutation hotspots in acute myeloid leukemia. Biology 11(2):161-617, 2022. e-Pub 2022. PMID: 35205028.
- Zhang, YH, Han, X. Acute promyelocytic leukemia with Chediak-Higashi like giant granules. Blood 139(1):149, 2022. e-Pub 2022. PMID: 34989769.
- Zhang YH, Han X. Acute promyelocytic leukemia with Chediak-Higashi like giant granules. Blood 139(1):149, 2022. e-Pub 2022.
- Wu L, Xia MR, Sun XP, Xin Han X, Zu YL, Jabbour EJ, You MJ, Lin P, Li SY, Xu J, Han HB, Bueso-Ramos CE, Medeiros LJ, Qiu XY, Yin CC. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol 105(4):449-459, 2020. e-Pub 2020. PMID: 32535947.
- Abbas HA, Han X. Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia. The New England Journal of Medicine 380(24):2360, 2019. e-Pub 2019.
- Mah A, Viola GM, Heredia EA, Rezvani K, Kebriaei P, Bhatti MM, Han X, Shpall EJ, Mulanovich VE. Graft loss attributed to possible transfusion‐transmitted ehrlichiosis following cord blood stem cell transplant. Transplant Infectious Disease 20(4):e12899, 2018. e-Pub 2018.
- Kurt H, Zheng L, Kantarjian HM, Tang GL, Ravandi-Kashani F, Garcia-Manero G, Gong ZM, Amin H, Konoplev S, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu SM. Secondary t(9;22)(q34;q11.2)/BCR-ABL1 rearrangement acquired during therapy of acute leukemia. Modern Pathology 31:1141-54, 2018. e-Pub 2018.
- Han X, Medeiros LJ, Zhang YH, You MJ, Andreeff M, Konopleva M, Bueso-Ramos CE. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia 16(Supplement):S30–S38, 2016. e-Pub 2016.
- Kang XL, Lu ZG, Cui CH, Deng M, Fan YQ, Dong BJ, Han X, Xie FC, Tyner JW, Coligan JE, Collins RH, Xiao XS, You MJ, and Zhang CC. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nature Cell Biology 17(5):665-677, 2015. e-Pub 2015.
- Mallampati S, Leng XH, Ma HQ, Zeng JF, Li J, Wang HY, Lin K, Lu Y, Yang Y, Sun BH, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, Cai Z, Fang BL, Shen HF, Han X, Hirsh-Ginsberg CF, Gao XL, Paranjape AN, Mani SA, Clise-Dwyer K, and Sun XP. Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL1 acute lymphoblastic leukemia. Blood 125(19):2968-73, 2015. e-Pub 2015.
- Liang M, Han X, Vadhan-Raj S, Nguyen M, Zhang YH, Fernandez M, Drakos E, Konoplev S, Yin C, Miranda R, McDonnell T, Medeiros LJ, Bueso-Ramos C. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Modern Pathology 23(3):381-391, 2010. e-Pub 2010.
- Quinitas-Cardama A, Han X, Kantarjian HM, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-263, 2009. e-Pub 2009.
- Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematological malignancies and recipients of allogeneic hematopoietic stem cell transplants. Cancer 110:1303-1306, 2007. e-Pub 2007.
- Han X, Shen T, Rojas-Espaillat LA, Hernandez E. Giant cell fibroblastoma of the vulva at the site of a previous fibroepithelial stromal polyp: a case report. J Low Genit Tract Dis 11:112-117, 2007. e-Pub 2007.
- Han X, Bueso-Ramos C. Precursor T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol 127:528-544, 2007. e-Pub 2007.
- Han X, Guillermo G, McDonnell TJ, Lozano G, Medeiros JL, Xiao L, Rosner G, Nguyen MH, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. MDM4 (MDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathol 20(1):54-62, 2007. e-Pub 2007.
- Han X, Medeiros JL, Abruzzo LV, Jones D, Lin P. Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis. Am J Clin Pathol 125(1):49-56, 2006. e-Pub 2006.
- Han X, Fiehler R, Broze Jr GJ. Characterization of the protein Z-dependent protease inhibitor. Blood 96(9):3049-3055, 2000. e-Pub 2000.
- Han X, Thomas G, Pamela B, Abendschein DR, Broze Jr GJ. Structural requirements for TFPI-mediated inhibition of intimal thickening after balloon injury in rat. Arteriosclerosis, Thrombosis, and Vascular Biology 19(10):2563-2567, 1999. e-Pub 1999.
- Han X, Huang Z, Fiehler R, Broze Jr GJ. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 38:11073-11078, 1999. e-Pub 1999.
- Han X, Ryan F, Broze Jr GJ. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 95(16):9250-9255, 1998. e-Pub 1998.
- Qiliang Q, Chen L, Ni Y, Han X, Xu Y, Wang Z. Significance of measuring urokinase type plasminogen activator in carcinoma tissues of the gastrointestinal and lung malignant tumors. Chinese Journal of Pathology 9:36-38, 1993. e-Pub 1993.
- Han X, Ren W, Xu Y, Chi C, Wang Z. Determination of plasma and tissue t-PA, PAI, Fn in patients with digestive tumor and its relationship with metastasis. Chinese Journal of Hematology 12:466-468, 1991. e-Pub 1991.
Review Articles
- Han X, Bueso-Ramos CE. Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. Annals Diagnostic Pathologyl 9(4):239-57, 2005. e-Pub 2005. PMID: 16084461.
Professional Educational Materials
- Lyapichev KA, Han X. Circulating prolymphocytes in B cell prolymphocytic leukemia (B-PLL). American Hematology Association, Blood Image Bank, 2018.
Abstracts
- Zhang WG, Ly C, Zhang Q, Mu H, Battula VL, Patel N, Schober W, Han X, Fogler WE, Magnani JL, Andreeff M. Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model. Blood 128:3519, 2016. e-Pub 2016.
- Zhang LP, Yang YL, Miranda R, Dave SK, Han X, Huang XY, Jin PJ, Medeiros LJ, Bueso-Ramos CE, You MJ. Expression of MicroRNA-150 Is Significantly Decreased in T-Acute Lymphoblastic Leukemia (T-ALL) and Inhibits T-ALL Cell Growth. Modern Pathology 27(Supplement 2):388A, 2014. e-Pub 2014.
- Yang YL, Gao XH, Han X, Huang XY, Liu Q, Zhang YH, Yin CC, Chen L, You MJ. Inactivation of INK4a/ARF accelerates the development of PTEN deficient T-ALL. Post presentation at 52nd American Society of Hematology Annual Meeting, Orlando, Florida 116(21):1706, 2010. e-Pub 2010.
- Zhao C, Han X, Zhang YH, Huang XY, Dai A, Lu G, Yin CC, Chen L, You MJ. Frequent epigenetic inactivation of MSX2 in acute myeloid leukemia. 52nd American Society of Hematology Annual Meeting 116(21):abstract # 4645, 2010. e-Pub 2010.
- Dai A, Chen Z, Yin CC, Chen L, Sun X, Dave S, Zhang YH, Han X, You MJ. Hypermethylation of DBCCR1 gene in acute myeloid leukemia. Post presentation at AACR 101st Annual Meeting 2010 in Washington, DC, 2010. e-Pub 2010.
- Gurevich I, Zhao C, Yin CC, Han X, Lin P, Gao X, Pan E, Medeiros LJ, Bueso-Ramos C, and You MJ. Aberrant PTEN expression pattern in acute myeloid leukemia. Modern Pathology 23(Supplement 1):299A-300A, 2010. e-Pub 2010.
- Zhao C, Dai A, Chen L, Sun X, Han X, Yin CC, You MJ. Epigenetic inactivation of DBC1 in acute myeloid leukemia. Blood 114(22):4429, 2009. e-Pub 2009.
- Liang M, Han X, Fernandez M, Nguyen M, Rassidakis GZ, Drakos I, Medeiros LJ, Bueso-Ramos CE. Inhibition of HDM4 induces p21 expression in mantle cell lymphoma. Modern Pathology 22(Supplemental 1):274A, 2009. e-Pub 2009.
- Liang M, Han X, Fernandez M, Nguyen M, Rassidakis GZ, Drakos I, Medeiros LJ, and Bueso-Ramos CE. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces the expression of p21. Post presentation at XIV Meeting of the European Association for Haematopathology. Bordeaux, France, 2008, 2008. e-Pub 2008.
- Liang M, Han X, Fernandez M, Nyugen MH, Rassidakis GZ, Drakos I, Medeiros LJ, Bueso-Ramos CE. Analysis of MDM4 expression, a key regulator of p53, in B-cell non-Hodgkin lymphomas: The HDM4-S splice mRNA variant is aberrantly overexpressed in mantle cell lymphoma. Modern Pathology 21(1):263A, 1201 Suppl, 2008. e-Pub 2008.
- Quinitas-Cardama A, Han X, Kantarjian HM, Cortes J. Dasatinib-induced platelet dysfunction. Blood 110(11):864A, Part 1, 2007. e-Pub 2007.
- Han X, Nguyen MH, Fernandez M, Broze GJ, Bueso-Ramos CE. Thrombin-releasable protein Z-dependent protease inhibitor identified in platelets and is likely due to uptake from plasma. Blood 110(11):520A, 1751 Part 1, 2007. e-Pub 2007.
- Sun X, Han X, Ginsberg C, Gong Y, and Irvin N. A novel type of inclusion in peripheral blood neutrophils. American Journal of Clinical Pathology 128:697, 2007. e-Pub 2007.
- Han X, Garcia-Manero G, Rassidakis GZ, Nguyen MH, Fernandez M, Bueso-Ramos CE. Down-regulation of HDM4 is associated with up-regulation of p21 and growth arrest in leukemia cells. Modern Pathology 20(3):243A, 1112 Suppl, 2007. e-Pub 2007.
- Han X, Garcia-Manero G, McDonnell T, Lozano G, Medeiros LJ, Rosner G, Hayes KJ, Bueso-Ramos CE. MDMX is widely expressed in adult precursor B cell acute lymphoblastic leukemia and is a potential therapeutic target. Blood 106(11):917A, 3280 Part 1, 2005. e-Pub 2005.
- Han X, McDonnell TJ, Lozano G, Garcia-Manero G, Medeiros LJ, Rassidakis GZ, Bueso-Ramos CE. MDMX is widely expressed in adult pre-B acute leukemia (ALL) and is a potential therapeutic target. Modern Pathology 18(1):233A, 1081 Suppl, 2005. e-Pub 2005.
- Han X, Fiehler R, Broze Jr GJ. Characterization of a protein Z-dependent plasma protease inhibitor. Oral presentation on American Society of Hematology Annual Meeting, New Orleans, 1999. e-Pub 1999.
- Han X, Zhan W, Wang L, Wang Z. Study on monoclonal antibodies specific for activation peptides in humn FIX and FX. Thrombosis Research 63:265, 1991. e-Pub 1991.
- Wang Z, Han X, Ren W, Xu Y, Chi C. Significance of the contrast of tumor plasminogen activator with fibronectin content in the pathogenesis of cancer metastasis. Oral Presentation on the First Chinese Japanese Symposium on Blood Coagulation, Fibrinolysis and Platelet, Hangzhou:37, 1990. e-Pub 1990.
- Han X, Ren W, Xu Y, Chi C, Wang Z. Determination of plasma and tissue t-PA, PAI, Fn in patients with digestive tumor and its relationship with metastasis. Oral presentation on Annual Meeting of Chinese Society of Hematology, Suzhou, 1990. e-Pub 1990.
- Han X, Xu Y, Wang Z, Chi C. Significance of the reversible binding of tissue plasminogen activator with fibronectin. Post presentation at XIIth Congress of the International Society on Thrombosis and Haemostasis, Tokyo:1090, 1989. e-Pub 1989.
Book Chapters
- Han X, Zhou H. Classification of Hematopoietic Neoplasms. In: Choosing Wisely: Laboratory Tests for Hematologic Neoplasms. People's Health Publisher, 1-6, 2000.
- Han X, Zhou H. Laboratory Tests for Hematopoietic Neoplasms. In: Choosing Wisely: Laboratory Tests for Hematologic Neoplasms. People's Health Publisher, 1-6, 2000.
- Han X, Ou C. Blastosis. In: Choosing Wisely: Laboratory Tests for Hematologic Neoplasms. People's Health Publisher, 187-190, 2000.
Letters to the Editor
- Hu, Z, Yin, CC, Sun, X, Han, X, Wang, W, Wang, S, You, MJ. A diagnostic dilemma for a patient with skin lesions and marked leukocytosis. Pathology 57: 371-374, 2025.
- Jia YN, Zhang WG, Basyal M, Chang KH, Ostermann L, Burks JK, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M. FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia 37: 1379–1383, 2023.
Patient Reviews
CV information above last modified July 22, 2026